6 Verzeichnisse
6.1 Literaturverzeichnis
13 Gianni L, Dafni U, Gelber RD, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011; 12(3): 236-44.
14 Millar EK, Graham PH, McNeil CM, et al. Prediction of outcome of early ER+
breast cancer is improved using a biomarker panel, which includes Ki-67 and p53. Br J Cancer. 2011; 105: 272-80.
15 Janicke F, Prechtl A, Thomssen C, et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor urokinase-type 1. J Natl Cancer Inst. 2001; 93(12): 913-20.
16 Harbeck N, Kates RE, Look MP, et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
Cancer Res. 2002; 62(16): 4617-22.
17 Mook S, Van't Veer LJ, Rutgers EJ, Piccart-Gebhart MJ, Cardoso F.
Individualization of therapy using Mammaprint: from development to the MINDACT Trial. Cancer Genomics Proteomics. 2007; 4(3): 147-55.
18 Cronin M, Pho M, Dutta D, et al. Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol. 2004; 164(1): 35-42.
19 Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol.
2006; 24(23): 3726-34.
20 Filipits M, Rudas M, Jakesz R, et al. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011; 17(18): 6012-20.
21 Kreienberg R, Albert U, Follmann M, Koop I. Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. 2012; 3. Auflage: 66-186.
22 Untch M, von Minckwitz G. Recent advances in systemic therapy: advances in neoadjuvant (primary) systemic therapy with cytotoxic agents. Breast Cancer Res.
2009; 11(2): 203.
23 Arteaga CL, Sliwkowski MX, Osborne CK, Perez EA, Puglisi F, Gianni L.
Treatment of HER2-positive breast cancer: current status and future perspectives. Nat
24 Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science. 1996; 272(5260): 408-11.
25 Allfrey VG, Mirsky AE. Structural Modifications of Histones and their Possible Role in the Regulation of RNA Synthesis. Science. 1964; 144(3618): 559.
26 Rundlett SE, Carmen AA, Kobayashi R, Bavykin S, Turner BM, Grunstein M.
HDA1 and RPD3 are members of distinct yeast histone deacetylase complexes that regulate silencing and transcription. Proc Natl Acad Sci U S A. 1996; 93(25): 14503-8.
27 de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003;
370(Pt 3): 737-49.
28 Blander G, Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem. 2004; 73: 417-35.
29 Gray SG, Ekstrom TJ. The human histone deacetylase family. Exp Cell Res.
2001; 262(2): 75-83.
30 Verdin E, Dequiedt F, Kasler HG. Class II histone deacetylases: versatile regulators. Trends Genet. 2003; 19(5): 286-93.
31 Gao L, Cueto MA, Asselbergs F, Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family.
J Biol Chem. 2002; 277(28): 25748-55.
32 Strahl BD, Allis CD. The language of covalent histone modifications. Nature.
2000; 403(6765): 41-5.
33 Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001; 1(3): 194-202.
34 Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 2007; 26(37):
5420-32.
35 Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene. 2005; 363: 15-23.
36 Kim HJ, Bae SC. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res. 2011; 3(2): 166-79.
37 Marks PA, Xu WS. Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem. 2009; 107(4): 600-8.
38 Wolffe AP, Urnov FD, Guschin D. Co-repressor complexes and remodelling chromatin for repression. Biochem Soc Trans. 2000; 28(4): 379-86.
39 Murphy M, Ahn J, Walker KK, et al. Transcriptional repression by wild-type p53 utilizes histone deacetylases, mediated by interaction with mSin3a. Genes Dev. 1999;
13(19): 2490-501.
40 Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol. 2000; 184(1): 1-16.
41 Emanuele S, Lauricella M, Tesoriere G. Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review). Int J Oncol. 2008; 33(4): 637-46.
42 Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
Oncologist. 2007; 12(10): 1247-52.
43 Campas-Moya C. Romidepsin for the treatment of cutaneous T-cell lymphoma.
Drugs Today (Barc). 2009; 45(11): 787-95.
44 Mund C, Lyko F. Epigenetic cancer therapy: Proof of concept and remaining challenges. Bioessays. 2010; 32(11): 949-57.
45 Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem.
1990; 265(28): 17174-9.
46 Qiu L, Burgess A, Fairlie DP, Leonard H, Parsons PG, Gabrielli BG. Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells. Mol Biol Cell. 2000; 11(6): 2069-83.
47 Sandor V, Senderowicz A, Mertins S, et al. P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer. 2000; 83(6): 817-25.
48 Zhang Y, Adachi M, Kawamura R, Imai K. Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis. Cell Death Differ. 2006;
13(1): 129-40.
49 Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET, Yu Q. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci U S A. 2005; 102(44): 16090-5.
50 Jeong JW, Bae MK, Ahn MY, et al. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell. 2002; 111(5): 709-20.
51 Deroanne CF, Bonjean K, Servotte S, et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling. Oncogene.
52 Bali P, Pranpat M, Bradner J, et al. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J Biol Chem. 2005; 280(29):
26729-34.
53 Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007; 25(21): 3109-15.
54 Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006; 6(1): 38-51.
55 Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19(5): 403-10.
56 Wittekind C MH. TNM Klassifikation maligner Tumoren. 2010; 7. Auflage: 169-81.
57 Remmele W SH. Recommendation for uniform definition of an immunoreactive score (IRS) for immunhistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe. 1987; 8: 138-40.
58 Krusche CA, Wulfing P, Kersting C, et al. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat. 2005; 90(1): 15-23.
59 Yoo CB, Jones PA. Epigenetic therapy of cancer: past, present and future. Nat Rev Drug Discov. 2006; 5(1): 37-50.
60 Zhang Z, Yamashita H, Toyama T, et al. Quantitation of HDAC1 mRNA expression in invasive carcinoma of the breast. Breast Cancer Res Treat. 2005; 94(1):
11-6.
61 Metivier R, Penot G, Hubner MR, et al. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell.
2003; 115(6): 751-63.
62 Kawai H, Li H, Avraham S, Jiang S, Avraham HK. Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor alpha. Int J Cancer. 2003; 107(3): 353-8.
63 Hu X, Stern HM, Ge L, et al. Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol Cancer Res. 2009; 7(4): 511-22.
64 Yang X, Ferguson AT, Nass SJ, et al. Transcriptional activation of estrogen receptor alpha in human breast cancer cells by histone deacetylase inhibition. Cancer Res. 2000; 60(24): 6890-4.
65 Zhou Q, Atadja P, Davidson NE. Histone deacetylase inhibitor LBH589 reactivates silenced estrogen receptor alpha (ER) gene expression without loss of DNA hypermethylation. Cancer Biol Ther. 2007; 6(1): 64-9.
66 deFazio A, Chiew YE, Donoghue C, Lee CS, Sutherland RL. Effect of sodium butyrate on estrogen receptor and epidermal growth factor receptor gene expression in human breast cancer cell lines. J Biol Chem. 1992; 267(25): 18008-12.
67 Reid G, Metivier R, Lin CY, et al. Multiple mechanisms induce transcriptional silencing of a subset of genes, including oestrogen receptor alpha, in response to deacetylase inhibition by valproic acid and trichostatin A. Oncogene. 2005; 24(31):
4894-907.
68 Bicaku E, Marchion DC, Schmitt ML, Munster PN. Selective inhibition of histone deacetylase 2 silences progesterone receptor-mediated signaling. Cancer Res. 2008;
68(5): 1513-9.
69 Linares A, Dalenc F, Balaguer P, Boulle N, Cavailles V. Manipulating protein acetylation in breast cancer: a promising approach in combination with hormonal therapies? J Biomed Biotechnol. 2011; doi:10.1155/2011/856985.
70 Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med. 2001; 344(8): 539-48.
71 Hirokawa Y, Arnold M, Nakajima H, Zalcberg J, Maruta H. Signal therapy of breast cancers by the HDAC inhibitor FK228 that blocks the activation of PAK1 and abrogates the tamoxifen-resistance. Cancer Biol Ther. 2005; 4(9): 956-60.
72 Fan J, Yin WJ, Lu JS, et al. ER alpha negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor. J Cancer Res Clin Oncol. 2008; 134(8): 883-90.
73 Sabnis GJ, Goloubeva O, Chumsri S, Nguyen N, Sukumar S, Brodie AM.
Functional activation of the estrogen receptor-alpha and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res. 2011; 71(5):
1893-903.
74 Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244(4905): 707-12.
75 Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene. 2000; 19(53): 6102-14.
76 Bali P, Pranpat M, Swaby R, et al. Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. Clin Cancer Res. 2005;
11(17): 6382-9.
77 Fuino L, Bali P, Wittmann S, et al. Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B. Mol Cancer Ther. 2003; 2(10): 971-84.
78 Munster PN, Troso-Sandoval T, Rosen N, Rifkind R, Marks PA, Richon VM. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells. Cancer Res. 2001; 61(23): 8492-7.
79 Weichert W, Roske A, Niesporek S, et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res. 2008; 14(6): 1669-77.
80 Weichert W, Roske A, Gekeler V, et al. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer. 2008; 98(3): 604-10.
81 Weichert W, Roske A, Gekeler V, et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 2008; 9(2): 139-48.
82 Suzuki J, Chen YY, Scott GK, et al. Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin Cancer Res.
2009; 15(9): 3163-71.
83 Zhang Z, Yamashita H, Toyama T, et al. HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res. 2004; 10(20): 6962-8.
84 Saji S, Kawakami M, Hayashi S, et al. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene. 2005; 24(28): 4531-9.
85 Ropero S, Fraga MF, Ballestar E, et al. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat Genet. 2006;
38(5): 566-9.
86 Weichert W. HDAC expression and clinical prognosis in human malignancies.
Cancer Lett. 2009; 280(2): 168-76.
87 Weichert W, Denkert C, Noske A, et al. Expression of class I histone deacetylases indicates poor prognosis in endometrioid subtypes of ovarian and endometrial carcinomas. Neoplasia. 2008; 10(9): 1021-7.
88 Khochbin S, Verdel A, Lemercier C, Seigneurin-Berny D. Functional significance of histone deacetylase diversity. Curr Opin Genet Dev. 2001; 11(2): 162-6.
89 Meehan WJ, Samant RS, Hopper JE, et al. Breast cancer metastasis suppressor 1 (BRMS1) forms complexes with retinoblastoma-binding protein 1 (RBP1) and the mSin3 histone deacetylase complex and represses transcription. J Biol Chem. 2004;
279(2): 1562-9.
90 Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood.
2007; 109(1): 31-9.
91 Vansteenkiste J, Van Cutsem E, Dumez H, et al. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer.
Invest New Drugs. 2008; 26(5): 483-8.
92 Luu TH, Morgan RJ, Leong L, et al. A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study.
Clin Cancer Res. 2008; 14(21): 7138-42.
93 Molife LR, Attard G, Fong PC, et al. Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Ann Oncol. 2010; 21(1): 109-13.
94 Whitehead RP, Rankin C, Hoff PM, et al. Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336). Invest New Drugs. 2009; 27(5): 469-75.
95 Schrump DS, Fischette MR, Nguyen DM, et al. Clinical and molecular responses in lung cancer patients receiving Romidepsin. Clin Cancer Res. 2008; 14(1): 188-98.
96 Stadler WM, Margolin K, Ferber S, McCulloch W, Thompson JA. A phase II study of depsipeptide in refractory metastatic renal cell cancer. Clin Genitourin Cancer. 2006;
5(1): 57-60.
97 Gore L, Rothenberg ML, O'Bryant CL, et al. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res. 2008; 14(14): 4517-25.
98 Rathkopf D, Wong BY, Ross RW, et al. A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2010; 66(1): 181-9.
99 Ramalingam SS, Parise RA, Ramanathan RK, et al. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res. 2007;
13(12): 3605-10.
100 Ramalingam SS, Maitland ML, Frankel P, et al. Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol. 2010; 28(1): 56-62.
101 Arce C, Perez-Plasencia C, Gonzalez-Fierro A, et al. A proof-of-principle study of epigenetic therapy added to neoadjuvant doxorubicin cyclophosphamide for locally advanced breast cancer. PLoS One. 2006; 1: e98.
102 Fernandez-Sanchez M, Gamboa-Dominguez A, Uribe N, et al. Clinical and pathological predictors of the response to neoadjuvant anthracycline chemotherapy in locally advanced breast cancer. Med Oncol. 2006; 23(2): 171-83.
103 Munster PN, Marchion D, Thomas S, et al. Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.
Br J Cancer. 2009; 101(7): 1044-50.
104 Munster P, Marchion D, Bicaku E, et al. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin Cancer Res. 2009; 15(7): 2488-96.
105 Perez-Plasencia C, Duenas-Gonzalez A. Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy? Mol Cancer. 2006; 5: 27.
106 Thurn KT, Thomas S, Moore A, Munster PN. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer. Future Oncol. 2011; 7(2):
263-83.
107 Munster PN, Thurn KT, Thomas S, et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011; 104: 1828-1835 108 Conte P, Campone M, Pronzato P, et al. Phase I trial of panobinostat (LBH589) in combination with trastuzumab in pretreated HER2-positive metastatic breast cancer (mBC): Preliminary safety and tolerability results. J Clin Oncol 2009; 27: 1081
109 Marchion DC, Bicaku E, Turner JG, Schmitt ML, Morelli DR, Munster PN.
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability. Mol Cancer Ther. 2009; 8(4): 794-801
6.2 Tabellenverzeichnis
Tabelle 1: Molekulare Subtypen des Mammakarzinoms nach aktuellen St. Gallen
Kriterien 2011 ... 10
Tabelle 2: Übersicht über nicht-Histon Proteine und deren Verhalten im deacetylierten Zustand ... 16
Tabelle 3: Übersicht der wichtigsten Vertreter der HDACi ... 18
Tabelle 4: Charakteristik der pathologischen Parameter des Kollektivs ... 23
Tabelle 5: Übersicht des Immunoreaktiven Scores ... 31
Tabelle 6: Verteilung der HDAC-Expression im Kollektiv ... 35
Tabelle 7: HDAC1-Korrelationen mit klinisch-pathologischen Parametern ... 39
Tabelle 8: HDAC2-Korrelationen mit klinisch-pathologischen Parametern ... 43
Tabelle 9: HDAC3-Korrelationen mit klinisch-pathologischen Parametern ... 46
Tabelle 10: Übersicht aktueller Therapiekombinationen mit HDACi verschiedener Tumorentitäten ... 62
Tabelle 11: Überblick der klinischen Studien zur Kombinationstherapie von HDACi und HT im Mammakarzinom ... 64
6.3 Abbildungsverzeichnis
Abb. 1: Zusammenspiel von HDAC und HAT ... 14
Abb. 2: Starke und negative HDAC1-Expression im Mammakarzinom ... 36
Abb. 3: Starke und negative HDAC2-Expression im Mammakarzinom ... 36
Abb. 4: Starke und negative HDAC3-Expression im Mammakarzinom ... 37
Abb. 5: Signifikante Korrelationen der HDAC1-Expression mit dem positiven Hormonrezeptorstatus ... 38
Abb. 6: Signifikante Korrelationen der HDAC2-Expression mit entdifferenzierten Tumoren (G3) ... 41
Abb. 7: Signifikante Korrelationen der HDAC2-Expression mit dem negativen Hormonrezeptorstatus ... 41
Abb. 8: Signifikante Korrelationen der HDAC2-Expression mit dem positiven HER2-Status ... 42
Abb. 9: Signifikante Korrelationen der HDAC2-Expression mit dem positiven Nodalstatus ... 42
Abb. 10: Signifikante Korrelationen der HDAC3-Expression mit entdifferenzierten Tumoren (G3) ... 44
Abb. 11: Signifikante Korrelationen der HDAC3-Expression mit dem negativen Hormonrezeptorstatus ... 45
Abb. 12: Einfluss des Nodalstatus auf das Gesamtüberleben ... 47
Abb. 13: Einfluss des Gradings auf das Gesamtüberleben ... 48
Abb. 14: Einfluss der Tumorgröße, angegeben im pT-Stadium auf das Gesamtüberleben ... 48
Abb. 15: Einfluss der HDAC3-Expression im Gesamtkollektiv auf das Gesamtüberleben ... 49
Abb. 16: Prognostisch günstiger Einfluss der HDAC3-Expression in der Subgruppe der Fälle von 1995-1999 ... 50
Abb. 17: Prognostisch günstiger Einfluss der HDAC3 Expression in der Subgruppe der Fälle von 1995-1999 ... 50
Abb. 18: Nachweis der HDAC-Expression im Westernblot ... 51